Standalone figures · ₹ crore · years without a filed annual are summed from quarters
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 926 | 1,014 | 1,300 | 1,590 | 1,507 | 1,720 | 1,943 | 2,023 | 1,785 | 1,860 | 1,713 | |
| COGS | -16 | -179 | 699 | 854 | 776 | 908 | 996 | 1,107 | 825 | 837 | 762 |
| Gross profit | — | — | 601 | 736 | 731 | 812 | 946 | 916 | 960 | 1,023 | 951 |
| 761 | 996 | 359 | 438 | 458 | 489 | 606 | 659 | 693 | 694 | 730 | |
| 181 | 197 | 242 | 298 | 273 | 323 | 341 | 257 | 267 | 329 | 221 | |
| OPM % | 19.6% | 19.5% | 18.6% | 18.8% | 18.1% | 18.8% | 17.5% | 12.7% | 15% | 17.7% | 12.9% |
| Depreciation | 67 | 69 | 86 | 93 | 82 | 85 | 96 | 109 | 118 | 134 | 164 |
| Interest | 62 | 49 | 49 | 58 | 52 | 36 | 31 | 48 | 56 | 75 | 62 |
| 2 | 3 | 4 | 2 | -12 | 5 | 5 | 5 | 2 | 5 | -73 | |
| Profit before tax | 53 | 83 | 112 | 149 | 127 | 206 | 219 | 105 | 95 | 124 | -78 |
| Tax | 12 | 16 | 34 | 46 | 42 | 73 | 58 | 27 | 26 | 33 | -30 |
| Tax % | 22.5% | 19.4% | 30.7% | 30.9% | 33.3% | 35.5% | 26.6% | 25.6% | 27.2% | 26.6% | -37.7% |
| 41 | 67 | 77 | 103 | 84 | 133 | 161 | 78 | 70 | 91 | -49 | |
| PAT margin % | 4.5% | 6.6% | 5.9% | 6.5% | 5.6% | 7.7% | 8.3% | 3.9% | 3.9% | 4.9% | -2.8% |
| EPS (₹) | 5 | 8.1 | 9.4 | 8.4 | 6.9 | 10.8 | 13 | 6.4 | 5.6 | 7.4 | -4 |
| EPS adjusted (₹) | — | — | 6.3 | 8.4 | 6.9 | 10.8 | 13 | 6.4 | 5.6 | 7.4 | -3.9 |
| 19.9% | 20.9% | 12.8% | 14.4% | 17.5% | 18.5% | 12.3% | 18.9% | 21.3% | 19% | — | |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 653 | 732 | 792 | 909 | 1,043 | 1,109 | 1,163 | 1,238 | 1,174 |
| 574 | 600 | 561 | 609 | 674 | 748 | 815 | 762 | 681 | |
| 299 | 330 | 391 | 370 | 471 | 504 | 485 | 505 | 485 | |
| Total equity & liabilities | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 | 2,365 |
| 634 | 713 | 669 | 713 | 879 | 948 | 1,071 | 1,365 | 1,333 | |
| CWIP | 116 | 73 | 152 | 245 | 285 | 402 | 414 | 121 | 95 |
| Investments | 3 | 1 | 1 | 1 | 11 | 5 | 5 | 10 | 10 |
| 790 | 898 | 946 | 955 | 1,038 | 1,030 | 997 | 1,034 | 929 | |
| Total assets | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 | 2,365 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Pharmaceuticals | 1,021 | 32.8 | 1,479.6 | 281.8 | 1,197.8 | 2.74 |
| Crop Protection | 691.6 | 51.4 |
| ₹ Cr | Mar 2016 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 102 | 186 | 285 | 229 | 294 | 315 | 187 | 280 | 302 | |
| -43 | -125 | -164 | -156 | -284 | -292 | -174 | -137 | -145 | |
| -69 | -55 | -101 | -97 | -6 | -8 | -27 | -144 | -160 | |
| Net cash flow | -10 | — | — | -24 | 4 | 15 | -14 | 0 | -3 |
| Free cash flow | — | — | — | 229 | 20 | 13 | -18 | 143 | 154 |
| CFO / Operating profit % | 56.5% | 62.3% | 104.3% | 70.9% | 86.3% | 122.7% | 69.9% | 85.4% | 137% |
| 830.5 |
| 147.5 |
| 683 |
| 7.53 |
| Exceptional Item - Employee Benefit expense | 0 | -38 | 0 | 0 | — | — |
| Exceptional Item - Impairment charge | 0 | -47.1 | 0 | 0 | — | — |
| Unallocable | 0 | 0 | 55.3 | 737.1 | — | — |
₹ crore by fiscal year